A family's persistent efforts in unraveling the cause of their daughter's chronic nerve and muscular maladies led to the ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

Indiana saw the second biggest small business growth in July, while President Trump is expected to impose tariffs on medicine ...

The market is set to reach USD 1.69 billion by 2035, growing at a 5.2% CAGR from its 2025 valuation of USD 1.01 billion. This ...

The record-setting Alexandria lab lease in San Diego showcases how biotech has few big tenants left to take empty spaces.

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Ninety percent of parents, expectant parents said they'd want to know early about SMA, and 80% said not screening newborns ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...